Fiera Capital Corp raised its position in Edwards Lifesciences Corp (NYSE:EW) by 90.6% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 13,781 shares of the medical research company’s stock after acquiring an additional 6,549 shares during the period. Fiera Capital Corp’s holdings in Edwards Lifesciences were worth $2,600,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Princeton Global Asset Management LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Savior LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Evolution Wealth Advisors LLC raised its stake in shares of Edwards Lifesciences by 990.9% during the 4th quarter. Evolution Wealth Advisors LLC now owns 120 shares of the medical research company’s stock worth $28,000 after purchasing an additional 109 shares in the last quarter. 1776 Wealth LLC raised its stake in shares of Edwards Lifesciences by 97.6% during the 1st quarter. 1776 Wealth LLC now owns 162 shares of the medical research company’s stock worth $30,000 after purchasing an additional 80 shares in the last quarter. Finally, Sugarloaf Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $47,000. Hedge funds and other institutional investors own 81.22% of the company’s stock.
NYSE:EW opened at $218.81 on Friday. The stock has a fifty day moving average price of $212.94 and a 200-day moving average price of $222.43. The company has a market cap of $45.13 billion, a price-to-earnings ratio of 41.84, a PEG ratio of 2.75 and a beta of 0.85. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.47 and a current ratio of 3.36. Edwards Lifesciences Corp has a fifty-two week low of $154.52 and a fifty-two week high of $247.64.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.22. The firm had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.03 billion. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. The company’s revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.32 EPS. Research analysts predict that Edwards Lifesciences Corp will post 4.95 EPS for the current fiscal year.
In related news, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $202.34, for a total transaction of $4,623,469.00. Following the completion of the sale, the chief executive officer now directly owns 69,976 shares in the company, valued at approximately $14,158,943.84. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Huimin Wang sold 1,717 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $216.68, for a total value of $372,039.56. Following the sale, the vice president now owns 31,435 shares of the company’s stock, valued at $6,811,335.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,878 shares of company stock valued at $20,047,408. Corporate insiders own 1.48% of the company’s stock.
A number of equities research analysts have recently issued reports on EW shares. Raymond James upped their price objective on Edwards Lifesciences from $230.00 to $250.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $230.00 to $255.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Goldman Sachs Group started coverage on Edwards Lifesciences in a research note on Wednesday, February 12th. They set a “neutral” rating and a $253.00 price objective on the stock. Morgan Stanley upped their price objective on Edwards Lifesciences from $241.00 to $250.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Finally, Cfra boosted their target price on Edwards Lifesciences from $201.00 to $231.00 and gave the stock a “buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the stock. Edwards Lifesciences has a consensus rating of “Buy” and an average target price of $247.52.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Story: Earnings Per Share
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.